# Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women

> **NCT01150123** · PHASE1 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 678 (actual)

## Conditions studied

- Group B Streptococcus

## Interventions

- **BIOLOGICAL:** Group B streptococcus (GBS) vaccine- low dose
- **BIOLOGICAL:** Group B streptococcus (GBS) vaccine- High dose
- **BIOLOGICAL:** Placebo- Saline

## Key facts

- **NCT ID:** NCT01150123
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-11
- **Final completion:** 2012-10
- **Target enrollment:** 678 (ACTUAL)
- **Last updated:** 2017-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01150123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01150123, "Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01150123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*